INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///

RADIOLOGY /// BREAST

AI-enabled solution to screen, detect, and track changes in lesions suspected of breast cancer

image description

Tempus Pixel provides advanced analysis and automated reporting from routine 2D and 3D mammograms to help improve efficiency and accuracy in detecting and longitudinal tracking of changes in lesions suspected of breast cancer.

Breast lesions identification

Automatically detects lesions suspected of breast cancer in 2D and 3D mammograms1,2

image description

Density assessment

Automatically generates reports that adhere to BI-RADS® tissue density categories from mammograms to help provide consistent breast anatomy assessments3

image description

Longitudinal tracking

Integrates results from prior exams into current breast screening evaluations to help efficiently and consistently monitor changes in lesions over time4

image description

worklist flagging

Automatically flags patient cases where the algorithm showed a higher confidence of a malignant finding, helping providers to timely review screening 2D and 3D breast images2

image description

Standardized image quality

Provides advanced embedded analytics to enable benchmarking, monitoring, trend-detection, and corrective actions based on analysis of routinely archived, prior mammograms and newly acquired mammograms

image description
  1. Conant EF, Toledano AY, Periaswamy S, et al. Improving accuracy and efficiency with concurrent use of artificial intelligence for digital breast tomosynthesis. Radiology: Artificial Intelligence. 2019;1(4):e180096. https://doi.org/10.1148/ryai.2019180096
  2. Tempus Pixel is FDA-cleared (K192437) and CE marked; detection of lesions suspected of breast cancer is powered by iCAD’s profound AI (K203822). Arterys Inc is the manufacturer of Tempus Pixel, excluding any third party components described in this list. iCAD is the manufacturer of ProFound AI. 
  3. Breast density assessment is powered by Densitas densityai™ (K192973) and is adjunctive but isn’t a diagnostic aid. Densitas is the manufacturer of the Breast density assessment.
  4. Tempus Pixel is FDA-cleared (K182034) and CE Marked. Detection of priors (currently in development) is powered by Therapixel. Arterys Inc is the manufacturer of Tempus Pixel, excluding any third party components described in this list.
  5. Quality analytics tools are powered by Densitas. Arterys Inc is the manufacturer of Tempus Pixel, excluding any third party components described in this list. Densitas is the manufacturer of intelliMammo™

Make more informed decisions with Tempus Pixel